MYC and neoplasm: Dual inhibition of PARP (Olaparib) and CDK4/6 (Palbociclib) inhibits the growth of ovarian cancer cells in vitro and slows down tumor growth in vivo in part by inducing homologous recombination (HR) deficiency in a MYC-dependent manner (92).